Tsai C H, Hill M, Drucker D J
Department of Medicine, University of Toronto, Ontario, Canada.
Am J Physiol. 1997 Mar;272(3 Pt 1):G662-8. doi: 10.1152/ajpgi.1997.272.3.G662.
Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 microg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P < 0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P < 0.05) and further increased after up to 14 days of GLP-2 treatment (P < 0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P < 0.01 vs. P < 0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P < 0.05 for im and ip, P < 0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.
胰高血糖素样肽2（GLP - 2）似乎能调节小肠上皮的生长。我们在体内研究了剂量、载体及给药途径对GLP - 2生物活性的重要性。皮下注射GLP - 2（每天两次，剂量为0.25至5.0微克）后，小鼠小肠重量增加；每天两次给予仅250纳克GLP - 2，持续14天，可检测到空肠隐窝加绒毛高度增加（比对照组高1.35倍，P < 0.05）。给予GLP - 2 6天后小肠重量增加（比对照组高1.4倍，P < 0.05），GLP - 2治疗长达14天后进一步增加（P < 0.001，GLP - 2与对照组相比）。GLP - 2以12%明胶或磷酸盐缓冲盐水（PBS）制剂形式给药均可增加小肠重量（明胶与PBS相比，分别为P < 0.01与P < 0.05），肌肉注射、腹腔注射或皮下注射GLP - 2后均具有肠营养作用（肌肉注射和腹腔注射P < 0.05，皮下注射P < 0.001，GLP - 2与对照组相比）。每天或隔天给予GLP - 2也可诱导肠道生长。这些结果确定了GLP - 2在体内活性的重要生物学参数。
